Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

News

Eilt: Erstklassige Studienergebnisse im Kampf gegen Hautkrebs. Neuer 217% Biotech Hot Stock nach 3.296% mit BioNTech ($BNTX), 10.996% mit Pfizer ($PFE), 31.205% mit Amgen ($AMG) und 134.452% mit Biogen ($BIIB). Jetzt 217% mit Biotech Aktientip Vidac : https://www.irw-press.at/prcom/images/messages/2023/71224/AC_VidacPharma_050723.001.png
Eilt: Erstklassige Studienergebnisse im Kampf gegen Hautkrebs. Neuer 217% Biotech Hot Stock nach 3.296% mit BioNTech ($BNTX), 10.996% mit Pfizer ($PFE), 31.205% mit Amgen ($AMG) und 134.452% mit Biogen ($BIIB). Jetzt 217% mit Biotech Aktientip Vidac

Eilt: Erstklassige Studienergebnisse im Kampf gegen Hautkrebs. Neuer 217% Biotech Hot Stock nach 134.452% mit Biogen

 

05.07.23 08:17

AC Research

 

London (www.aktiencheck.de, Anzeige)

 

 

Eilt: Erstklassige Studienergebnisse im Kampf gegen Hautkrebs. Neuer 217% Biotech Hot Stock nach 3.296% mit BioNTech ($BNTX), 10.996% mit Pfizer ($PFE), 31.205% mit Amgen ($AMG) und 134.452% mit Biogen ($BIIB). Jetzt 217% mit Biotech Aktientip Vidac : https://www.irw-press.at/prcom/images/messages/2023/71224/AC_VidacPharma_050723.001.png
Eilt: Erstklassige Studienergebnisse im Kampf gegen Hautkrebs. Neuer 217% Biotech Hot Stock nach 3.296% mit BioNTech ($BNTX), 10.996% mit Pfizer ($PFE), 31.205% mit Amgen ($AMG) und 134.452% mit Biogen ($BIIB). Jetzt 217% mit Biotech Aktientip Vidac

Eilt: Erstklassige Studienergebnisse im Kampf gegen Hautkrebs. Neuer 217% Biotech Hot Stock nach 134.452% mit Biogen

 

05.07.23 08:17

AC Research

 

London (www.aktiencheck.de, Anzeige)

 

 

Eilt: Sensationelle Studienergebnisse - Massives Kaufsignal. Neuer 224% Biotech Aktientip nach 3.296% mit BioNTech ($BNTX), 10.996% mit Pfizer ($PFE), 31.205% mit Amgen ($AMG) und 134.452% mit Biogen ($BIIB): https://www.irw-press.at/prcom/images/messages/2023/71203/Acresearch040723_01.001.png
Eilt: Sensationelle Studienergebnisse - Massives Kaufsignal. Neuer 224% Biotech Aktientip nach 3.296% mit BioNTech ($BNTX), 10.996% mit Pfizer ($PFE), 31.205% mit Amgen ($AMG) und 134.452% mit Biogen ($BIIB)

Eilt: Sensationelle Studienergebnisse - Massives Kaufsignal. Neuer 224% Biotech Aktientip nach 31.205% mit Amgen ($AMGN)

 

04.07.23

AC Research

 

London (www.aktiencheck.de, Anzeige)

 

 

Eilt: Sensationelle Studienergebnisse - Massives Kaufsignal. Neuer 224% Biotech Aktientip nach 3.296% mit BioNTech ($BNTX), 10.996% mit Pfizer ($PFE), 31.205% mit Amgen ($AMG) und 134.452% mit Biogen ($BIIB): https://www.irw-press.at/prcom/images/messages/2023/71203/Acresearch040723_01.001.png
Eilt: Sensationelle Studienergebnisse - Massives Kaufsignal. Neuer 224% Biotech Aktientip nach 3.296% mit BioNTech ($BNTX), 10.996% mit Pfizer ($PFE), 31.205% mit Amgen ($AMG) und 134.452% mit Biogen ($BIIB)

Eilt: Sensationelle Studienergebnisse - Massives Kaufsignal. Neuer 224% Biotech Aktientip nach 31.205% mit Amgen ($AMGN)

 

04.07.23

AC Research

 

London (www.aktiencheck.de, Anzeige)

 

 

Eilt: Sensationelle Studienergebnisse - Massives Kaufsignal. Neuer 224% Biotech Aktientip nach 3.296% mit BioNTech ($BNTX), 10.996% mit Pfizer ($PFE), 31.205% mit Amgen ($AMG) und 134.452% mit Biogen ($BIIB): https://www.irw-press.at/prcom/images/messages/2023/71203/Acresearch040723_01.001.png
Eilt: Sensationelle Studienergebnisse - Massives Kaufsignal. Neuer 224% Biotech Aktientip nach 3.296% mit BioNTech ($BNTX), 10.996% mit Pfizer ($PFE), 31.205% mit Amgen ($AMG) und 134.452% mit Biogen ($BIIB)

Eilt: Sensationelle Studienergebnisse - Massives Kaufsignal. Neuer 224% Biotech Aktientip nach 31.205% mit Amgen ($AMGN)

 

04.07.23

AC Research

 

London (www.aktiencheck.de, Anzeige)

 

 

Down Over 80%, is Pet Insurer Trupanion Worth the Risk Premium?: https://www.marketbeat.com/logos/articles/med_20230628085658_down-over-80-is-pet-insurer-trupanion-worth-the-ri.jpg
Down Over 80%, is Pet Insurer Trupanion Worth the Risk Premium?

As shareholders of pet insurer Trupanion Inc. (NASDAQ: TRUP) learned last month, when you post a net loss that's twice what Wall Street expected, things get a little fuzzy.

The May 5

MoonLake Immunotherapeutics Makes a Moonshot on Trials: https://www.marketbeat.com/logos/articles/med_20230627135359_chart-mltx.jpg
MoonLake Immunotherapeutics Makes a Moonshot on Trials

Clinical stage biotech MoonLake Immunotherapeutics AG (NASDAQ: MLTX) shares spiked 70% on positive phase two clinical trial results. The company specializes in nanobodies, fragments of antibodies

PetVivo Sales Spryng Higher on Injectable OA Relief for Pets: https://www.marketbeat.com/logos/articles/med_20230625124449_chart-petv.jpg
PetVivo Sales Spryng Higher on Injectable OA Relief for Pets

Developmental biomedical device company PetVivo Holdings Inc. (OTCMKTS: PETV) makes pet medical devices and therapeutics. What kind of medical devices would pets need? Pacemakers? Artificial hearts

Sarepta Therapeutics Gets FDA Nod, Drops Warning (or Opportunity?): https://www.marketbeat.com/logos/articles/med_20230627075714_sarepta-therapeutics-gets-fda-nod-drops-warning-or.jpg
Sarepta Therapeutics Gets FDA Nod, Drops Warning (or Opportunity?)

On May 15, Sarepta Therapeutics Inc. (NASDAQ: SRPT) learned that its treatment for Duchenne muscular dystrophy (DMD) was recommended for approval by the Food and Drug Administration (FDA)

ImmunoGen Stock Continues to Defy Gravity on Phase 2 Trials: https://www.marketbeat.com/logos/articles/med_20230625130240_chart-imgn2.jpg
ImmunoGen Stock Continues to Defy Gravity on Phase 2 Trials

ImmunoGen Inc. (NASDAQ: IMGN) is a commercial-stage biotechnology company leading in antibody-drug conjugates (ADC). ADCs are like heat-seeking missiles that target and selectively deliver

Patterson Companies Leverages Healthcare For Income Investors: https://www.marketbeat.com/logos/articles/med_20230621111455_chart-pdco-6212023.png
Patterson Companies Leverages Healthcare For Income Investors

Patterson Companies, Inc. (NASDAQ: PDCO) is a dual-story that includes healthcare for humans and animals. The company operates in 2 segments, Dental and Animal Health, and both are growing. The

Agilent Technologies Stock: Ready to Rise off the Floor: https://www.marketbeat.com/logos/articles/med_20230618154044_chart-a.jpg
Agilent Technologies Stock: Ready to Rise off the Floor

Agilent Technologies Inc. (NYSE: A) stock is underperforming the market, trading down 19% year-to-date. Agilent is a leading global provider of laboratory technologies and equipment.

It counts

DexCom Clears Base, Wall Street Eyes Double-Digit Earnings Growth: https://www.marketbeat.com/logos/articles/med_20230621092054_dexcom-clears-base-wall-street-eyes-double-digit-e.jpg
DexCom Clears Base, Wall Street Eyes Double-Digit Earnings Growth

You generally associate Super Bowl commercials with products made by PepsiCo Inc. (NYSE: PEP) or the Coca-Cola Co. (NYSE: KO), but earlier this year, glucose-monitoring geat maker DexCom Inc.

DexCom Clears Base, Wall Street Eyes Double-Digit Earnings Growth: https://www.marketbeat.com/logos/articles/med_20230621092054_dexcom-clears-base-wall-street-eyes-double-digit-e.jpg
DexCom Clears Base, Wall Street Eyes Double-Digit Earnings Growth

You generally associate Super Bowl commercials with products made by PepsiCo Inc. (NYSE: PEP) or the Coca-Cola Co. (NYSE: KO), but earlier this year, glucose-monitoring geat maker DexCom Inc.

Medical Stocks Waters, Agilent, Illumina Show Growth Potential: https://www.marketbeat.com/logos/articles/med_20230620074442_medicals-stocks-waters-agilent-illumina-show-growt.jpg
Medical Stocks Waters, Agilent, Illumina Show Growth Potential

Investors seeking growth often have no choice other than paying up for a stock with strong potential. However, there are some stocks that appear to be trading at low valuations relative to their

Medical Stocks Waters, Agilent, Illumina Show Growth Potential: https://www.marketbeat.com/logos/articles/med_20230620074442_medicals-stocks-waters-agilent-illumina-show-growt.jpg
Medical Stocks Waters, Agilent, Illumina Show Growth Potential

Investors seeking growth often have no choice other than paying up for a stock with strong potential. However, there are some stocks that appear to be trading at low valuations relative to their

Medical Stocks Waters, Agilent, Illumina Show Growth Potential: https://www.marketbeat.com/logos/articles/med_20230620074442_medicals-stocks-waters-agilent-illumina-show-growt.jpg
Medical Stocks Waters, Agilent, Illumina Show Growth Potential

Investors seeking growth often have no choice other than paying up for a stock with strong potential. However, there are some stocks that appear to be trading at low valuations relative to their

Surgical Centers, Med-Tech Stocks Up On Pent-Up Surgical Demand: https://www.marketbeat.com/logos/articles/med_20230616065107_surgical-centers-med-tech-stocks-up-on-pent-up-sur.jpg
Surgical Centers, Med-Tech Stocks Up On Pent-Up Surgical Demand

After a pandemic pause, hip and knee replacements are back. Long-postponed surgeries are being rescheduled, which is bad for business at insurance companies like UnitedHealth Group Inc. (NYSE:

Surgical Centers, Med-Tech Stocks Up On Pent-Up Surgical Demand: https://www.marketbeat.com/logos/articles/med_20230616065107_surgical-centers-med-tech-stocks-up-on-pent-up-sur.jpg
Surgical Centers, Med-Tech Stocks Up On Pent-Up Surgical Demand

After a pandemic pause, hip and knee replacements are back. Long-postponed surgeries are being rescheduled, which is bad for business at insurance companies like UnitedHealth Group Inc. (NYSE:

Is NexTier-Patterson UTI Deal A Sign Of More Consolidation Ahead?: https://www.marketbeat.com/logos/articles/med_20230616064654_is-nextier-patterson-uti-deal-a-sign-of-more-conso.jpg
Is NexTier-Patterson UTI Deal A Sign Of More Consolidation Ahead?

Shares of Patterson UTI Energy Inc. (NASDAQ: PTEN) and NexTier Oilfield Solutions (NYSE: NEX) were both trading higher on June 15 following news that the companies agreed to combine in a merger of

Bullish or Bearish? Vetting Animal Health Care Stocks: https://www.marketbeat.com/logos/articles/med_20230616064027_bullish-or-bearish-vetting-animal-health-care-stoc.jpg
Bullish or Bearish? Vetting Animal Health Care Stocks

Dogs and cats were among the biggest beneficiaries of the pandemic thanks to more attention from housebound pet owners. Pet adoption trends also skyrocketed. 

As Fido and Fluffy were spoiled more

Clarence Seedorf und Khabib Nurmagomedov unterzeichnen mit ihrer SK Sports Holding eine weltweite Partnerschaftsvereinbarung mit FITLIGHT: https://www.irw-press.at/prcom/images/messages/2023/70999/FITLIGHT_061523_DEPRcom.001.png
Clarence Seedorf und Khabib Nurmagomedov unterzeichnen mit ihrer SK Sports Holding eine weltweite Partnerschaftsvereinbarung mit FITLIGHT

 

FITLIGHT wird offizieller Technologiepartner von SK Sports Holding

 

MIAMI, FL / ACCESSWIRE / 15. Juni 2023 / SK Sports Holding, die im Jahr 2022 ihren ersten Seedorf Khabib Performance